24.01
price down icon1.83%   -0.4756
 
loading
Precedente Chiudi:
$24.49
Aprire:
$24.53
Volume 24 ore:
105.61K
Relative Volume:
0.12
Capitalizzazione di mercato:
$2.03B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-5.3247
EPS:
-4.51
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
-8.62%
1M Prestazione:
+3.85%
6M Prestazione:
-3.06%
1 anno Prestazione:
-13.98%
Intervallo 1D:
Value
$23.84
$24.71
Intervallo di 1 settimana:
Value
$23.62
$26.44
Portata 52W:
Value
$20.84
$49.50

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Nome
Beam Therapeutics Inc
Name
Telefono
857-327-8775
Name
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Dipendente
374
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BEAM's Discussions on Twitter

Confronta BEAM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
BEAM 24.01 2.03B 352.57M -143.01M -153.40M -4.51
VRTX 446.87 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.28 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.30 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.22 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.67 24.49B 3.30B -501.07M 1.03B 11.54

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-01-29 Aggiornamento JP Morgan Neutral → Overweight
2023-12-15 Downgrade BofA Securities Buy → Neutral
2023-12-08 Downgrade Jefferies Buy → Hold
2023-10-20 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-10-20 Downgrade Leerink Partners Outperform → Market Perform
2023-03-21 Iniziato Bernstein Mkt Perform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-12-13 Iniziato Citigroup Buy
2022-06-17 Iniziato BMO Capital Markets Market Perform
2022-04-28 Iniziato Credit Suisse Neutral
2022-01-05 Iniziato Guggenheim Buy
2021-10-19 Iniziato SVB Leerink Outperform
2021-09-24 Ripresa Stifel Buy
2021-09-10 Iniziato BofA Securities Buy
2021-05-11 Iniziato Redburn Buy
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-16 Iniziato Wells Fargo Overweight
2021-01-29 Downgrade JP Morgan Overweight → Neutral
2021-01-06 Iniziato Stifel Hold
2020-08-05 Iniziato William Blair Outperform
2020-03-02 Iniziato Barclays Overweight
2020-03-02 Iniziato JP Morgan Overweight
2020-03-02 Iniziato Jefferies Buy
2020-03-02 Iniziato Wedbush Outperform
Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

pulisher
Nov 19, 2024

Prime Editing and CRISPR Market Trends and Growth Opportunities - openPR

Nov 19, 2024
pulisher
Nov 16, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq

Nov 15, 2024
pulisher
Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™

Nov 11, 2024
pulisher
Nov 10, 2024

Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 09, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Beam Therapeutics president sells $1.35 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 08, 2024

Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN

Nov 07, 2024
pulisher
Nov 06, 2024

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Beam points to positive data with key base editing asset - pharmaphorum

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights

Nov 05, 2024
pulisher
Nov 05, 2024

SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s early base editing clinical data overshadowed by patient death - The Business Journals

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics to Present Data Across Hematology - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Posts Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Nov 05, 2024

Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Beam Therapeutics Inc Azioni (BEAM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Ciaramella Giuseppe
President
Oct 14 '24
Option Exercise
2.00
41,754
83,594
211,370
Ciaramella Giuseppe
President
Oct 14 '24
Sale
26.27
51,110
1,342,752
160,260
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):